EsoBiotec to present preclinical proof-of-concept data for ENaBL-T

EsoBiotec will present pre-clinical proof of concept data validating the company’s T cell targeting Engineered NanoBody Lentiviral vector, ENaBL-T, for in vivo CAR-T cell therapies. Data from three approved abstracts will be presented as posters at the American Society of Gene and Cell Therapy 28th Annual Meeting, taking place in New Orleans, Louisiana, from May 13-17, 2025. Details of the presentations: Poster Talk Title: ENaBL, a Novel Lentiviral Vector Platform for In Vivo Engineering of Therapeutic Anti-BCMA CAR T Cells, Shows Effective T Cell Transduction and Tumor Control in a Humanized Murine Model. Summary: Pre-clinical proof of concept data for the safety and efficacy of our lead candidate ENaBL-T BCMA CAR encoding vector, ESO-T01, in humanized mice. This data was used in support of the first in human testing of ESO-T01 initiated in November 2024 and demonstrates the potent in vivo reprogramming potential of ESO-T01 from a single injection of vector at a dose below 1E+06 TU. Poster Presentation Title: Development of Novel T Cell-Specific Synthetic Promoters for Safer and More Effective In Vivo CAR-T Cell Therapies. Summary: Design, testing and selection of a T cell specific synthetic promoter tailored for the lentiviral expression cassette of ENaBL-T. Use of the synthetic promoter to regulate expression of BCMA CAR transgene increased CAR-T function, as well as vector production yield. Presentation Title: Engineering T Cell-Specific Lentiviral Vectors for Safe and Effective In Vivo CAR-T Therapy. Summary: Discovery pre-clinical data supporting the selection of the targeting/transduction complex of ENaBL-T and the identification of new targeting deficient VSVG mutant. Associating the envelope anchored TCRab single domain antibody binder with VSVGI331 mutant results in activation, expansion and specific transduction of resting T cells, maximizing the potential for in vivo reprogramming in the absence of pre-conditioning.